Y mAbs Therapeutics — Q4 2023 Earnings Presentation
21 slides from Y mAbs Therapeutics's earnings presentation, Mar 1, 2024
Slide 1: Q4 & FY2023 Financial Results, Corporate Update and FY2024 Guidance
Q4 & FY2023 Financial Results, Corporate Update and FY2024 Guidance March 1, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre
Slide 3: Mike Rossi - Company Overview
Mike Rossi President and CEO Company Overview 3
Slide 4: Agenda
Agenda Company Overview 1 Mike Rossi, President and Chief Executive Officer DANYELZA U.S. Sales 2 Sue Smith, Chief Commercial Officer Ongoing Naxitamab Clinical Trials 3 Vignesh Rajah, MBBS, DCH, MRCP, Chief Medical Officer Q4 & FY2023 Financials and FY2024 Guidance 4 Bo Kruse, Chief Financial Offic
Slide 5: FY2023 Company Overview
FY2023 Company Overview Driving Commercial Capital Innovation Footprint Efficiency Self-Assembly DANYELZA Total FY2023 cash use DisAssembly (“SADA”) (naxitamab-gqgk) of $27.1 million Pretargeted marketed for Radioimmunotherapy R/R High-Risk $78.6 million cash and Platform (“PRIT”) Neuroblastoma cash
Slide 6: DANYELZA Commercial Performance
DANYELZA Commercial Performance • Q4 2023 DANYELZA net product revenues of $23.4 million, a 42% increase versus Q4 2022 and 17% increase versus Q3 2023 • FY2023 DANYELZA net product revenues of $84.3 million, a YoY increase of 71% versus FY2022 • Achieved top end of FY2023 guidance range of $80 mill
Slide 7: Current Radiopharma Challenges Negatively Impact Patient Care
Current Radiopharma Challenges Negatively Impact Patient Care Infrastructure and Physician Administration Continuing Drug Manufacturing Participation Sites Shortages Simpler, more user-friendly solutions greatly needed for physicians and patients 7
Slide 8: Study 1001: GD2-SADA Phase I Clinical Trial – Dosing Patients in Part A
Study 1001: GD2-SADA Phase I Clinical Trial – Dosing Patients in Part A Theranostic approach using a 30 mCi 177Lu-DOTA imaging dose before exposing to therapeutic dose Trial Update: › Solid tumors (SCLC, malignant melanoma, sarcomas) › 10 patients dosed to date › Completed Cohorts 1, 2 and 3; curren
Slide 9: Study 1201: Planned CD38-SADA Phase I Clinical Trial Design
Study 1201: Planned CD38-SADA Phase I Clinical Trial Design Theranostic approach using a 177Lu-DOTA imaging dose before exposure to a therapeutic 177Lu-DOTA dose Trial Update: › IND approved by U.S. FDA in Q4 2023 › On-track to dose first patient in 2024 Part A CD38-SADA dose-escalation with fixed i
Slide 10: Sue Smith - U.S. DANYELZA Sales
Sue Smith Chief Commercial Officer U.S. DANYELZA Sales 10
Slide 11: Q4 2023 DANYELZA U.S. Commercial Update
Q4 2023 DANYELZA U.S. Commercial Update • Q4 2023 DANYELZA net product revenues of $23.4 million, 42% YoY • FY2023 DANYELZA net product revenues of $84.3 million, 71% YoY • 58 U.S. accounts to date since initial launch; 10 new accounts added in FY2023 • 41 HCPs prescribed DANYELZA in 2023 with 8
Slide 12: Vignesh Rajah - Ongoing Naxitamab Clinical Trials
Vignesh Rajah Chief Medical Officer Ongoing Naxitamab Clinical Trials 12
Slide 13: Ongoing Naxitamab Clinical Trials
Ongoing Naxitamab Clinical Trials • Phase II BCC multi-center • Multi-center Phase II trial • ISS Phase Ib/II trial investigating TGFβ trial evaluating naxitamab + standard investigating naxitamab in patients NKs, gemcitabine + naxitamab in induction therapy in patients with with relapsed osteosarco
Slide 14: Bo Kruse - Q4 & FY2023 Financials and FY2024 Guidance
Bo Kruse Chief Financial Officer Q4 & FY2023 Financials and FY2024 Guidance 14
Slide 15: Key Q4 & FY2023 Financial Highlights - Revenue
Key Q4 & FY2023 Financial Highlights Revenue Three months ended Dec 31, Twelve months ended Dec 31, 2023 2022 2023 2022 Net product revenue $23.4 M $16.4 M $84.3 M $49.3 M License revenue - $15.0 M $0.5 M $16.0 M Total revenue $23.4 M $31.4 M $84.8 M $65.3 M Net product revenue Net product revenue Y
Slide 16: Key Q4 & FY2023 Financial Highlights - Operating Expenses
Key Q4 & FY2023 Financial Highlights Operating Expenses Three months ended Dec 31, Twelve months ended Dec 31, 2023 2022 2023 2022 Cost of goods sold $2.1 M $2.0 M $11.4 M $7.5 M License royalties - - $0.05 M $0.1 M Research & development $13.4 M $19.8 M $54.2 M $91.6 M Selling, general & admin $11.
Slide 17: Key Q4 & FY2023 Financial Highlights - Net Loss
Key Q4 & FY2023 Financial Highlights Net Loss Three months ended Dec 31, Twelve months ended Dec 31, 2023 2022 2023 2022 Net income/(loss) $(1.0) M $1.2 M $(21.4) M $(95.6) M Net income/(loss) per basic, $(0.02) $0.03 $(0.49) $(2.19) diluted share Net loss YoY Net loss YoY decrease of 17% decrease o
Slide 18: Key Q4 & FY2023 Financial Highlights - Responsible stewards of capital
Key Q4 & FY2023 Financial Highlights Responsible stewards of capital As of Twelve months ended Dec 31, Dec 31, 2023 Dec 31, 2022 2023 2022 Cash and cash equivalents $78.6 M $105.8 M Cash use $27.1 M $75.8 M Anticipated cash runway Annual cash use into 2027 reduced by 64% *This estimate reflects the
Slide 19: Financial Guidance for Full Year 2024
Financial Guidance for Full Year 2024 $95 million to $100 million DANYELZA Net Product Revenues 16%* versus FY2023 $115 million to $120 million Total Operating Expenses 6%* versus FY2023 $15 million to $20 million Total Expected Cash Burn 35%* versus FY2023 Cash and cash equivalents anticipate
Slide 20: Q&A
Q&A Mike Rossi Thomas Gad Sue Smith President and Founder, Vice Chair, Chief Commercial Officer Chief Executive Officer Chief Business Officer Vignesh Rajah, MBBS, Steen Lisby, MD, DMSc Bo Kruse DCH, MRCP Chief Scientific Officer Chief Financial Officer Chief Medical Officer 20
Slide 21: Thank You
Thank You